European Commission approves GSK’s recombinant zoster vaccine, Shingrix in prefilled syringe: London, UK Thursday, January 8, 2026, 09:00 Hrs [IST] GSK plc announced the Europea ...

A new global systematic review and meta-analysis has shown an association between herpes zoster vaccination, used to prevent shingles, and a statistically significant lower risk of heart attack and ...

The recombinant zoster vaccine (RZV; Shingrix) was associated with a significantly increased risk of recurrence of herpes zoster ophthalmicus (HZO), according to a retrospective cohort study. Within ...

The varicella-zoster virus (VZV) causes two distinct infections: varicella and herpes zoster. Varicella, commonly known as chickenpox, manifests as the primary infection with VZV, which is a member of ...

The shingles vaccine may offer a protective effect against developing dementia, as well as “therapeutic potential” for those ...

Low-dose suppressive valacyclovir treatment of herpes zoster ophthalmicus (HZO) did not show significant benefits at 12 months but showed treatment superiority at 18 months and a reduction in the ...

Please provide your email address to receive an email when new articles are posted on . The effectiveness of full vaccination was 73% after 3 to 4 years. In contrast, the effectiveness of partial ...

Shingrix, a recombinant zoster vaccine, combines glycoprotein E antigen with an adjuvant system called AS01B. It has been approved in the European Union for preventing herpes zoster and post-herpetic ...